MiMedx Group, Inc. (MDXG)
| Market Cap | 573.47M -51.2% |
| Revenue (ttm) | 418.63M +20.0% |
| Net Income | 48.58M +14.5% |
| EPS | 0.32 +13.1% |
| Shares Out | 148.57M |
| PE Ratio | 12.06 |
| Forward PE | 45.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 811,847 |
| Open | 3.860 |
| Previous Close | 3.880 |
| Day's Range | 3.840 - 3.945 |
| 52-Week Range | 3.770 - 7.990 |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+159.07%) |
| Earnings Date | Apr 29, 2026 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The co... [Read more]
Financial Performance
In 2025, MiMedx Group's revenue was $418.63 million, an increase of 19.99% compared to the previous year's $348.88 million. Earnings were $48.58 million, an increase of 14.52%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 159.07% from the latest price.
News
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWI...
MIMEDX Announces Launch of CHORIOFIX™
Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extens...
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjuste...
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth qu...
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
Agreement expands offering to include additional sheet, particulate and flowable products Agreement expands offering to include additional sheet, particulate and flowable products
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
Industry's Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications Industry's Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publica...
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to dist...
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following i...
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the ...
MIMEDX Announces Record Revenue for Third Quarter 2025
Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Shar...
MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29
MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third qua...
MIMEDX Announces Launch of EPIXPRESS®
Next-Generation, Lyophilized Human Placental Allograft Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products Next-Generation, Lyophilized Human Placental Allograft Further ...
MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall
To Present Six Posters Featuring the Company's Latest Product Innovations To Present Six Posters Featuring the Company's Latest Product Innovations
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results
Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06,...
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the compan...
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second qu...
MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026
New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securit...
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)
Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company'...
MIMEDX Announces First Quarter 2025 Operating and Financial Results
Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17...
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quar...
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference
MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Healt...
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results
Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted E...